Full and Booster Doses of SARS-CoV-2 mRNA-1273 Vaccine Increase Waning Antibody Levels After Completed Vaccination Among Dialysis Patients at a Large Dialysis Organization

Linda H Ficociello1, Joanna Willett1, Claudy Mullon1, Curtis Johnson2, Michael S Anger1, Jeffrey L Hymes1

1Global Medical Office, Fresenius Medical Care, Waltham, MS, USA; 2Spectra Laboratories, Southaven, MS, USA

Correspondence: Jeffrey L Hymes, Fresenius Medical Care, 1000 Corporate Centre Drive, Suite 400, Franklin, TN, 37067, USA, Email Jeffrey.HymesMD@freseniusmedicalcare.com

Antibody response to the primary 2-dose regimen of mRNA-based coronavirus disease 2019 (COVID-19) vaccines is reduced in dialysis populations vs healthy controls. Moreover, dialysis patients demonstrate a faster decline in antibody levels and diminished long-term antibody response than the general population. These findings support prioritizing this population for additional vaccine doses following primary vaccination. The antibody response following an initial 2-dose course of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-1273 vaccine and third “full” (100 mcg) or “booster” (50 mcg) doses has not been well characterized.

As part of a continuing quality improvement project, we examined antibody levels among patients who received 2 doses of the mRNA-1273 vaccine across 7 Fresenius Kidney Care clinics in Massachusetts, with follow-up antibody levels at least 250 days after completion of the primary vaccination series. Patients with evidence of any COVID-19 infection (eg, positive polymerase chain reaction test, elevated antibody levels prior to initial vaccination, and/or clinical symptoms of COVID-19), those who received >3 vaccine doses, and those who received other COVID-19 vaccines were excluded from the present analysis. Antibody testing was performed at a centralized laboratory using remnant blood samples originally collected for routine laboratory assessments. A semiquantitative chemiluminescent assay for immunoglobulin G directed against the receptor binding domain of the S1 subunit of the SARS-CoV-2 spike antigen (ADVIA Centaur® XP/XPT sCOVG; Siemens Healthcare Diagnostics Inc.; Tarrytown, NY) was used. Antibody levels were indexed between 0.5 and 750, with indices >1 considered reactive and those >7 considered to represent an “adequate” response.

Antibody levels were grouped according to time points relative to vaccine dose 1 (before dose 1; after dose 1 but before dose 2), dose 2 (0–15, 16–30, 31–60, 61–120, and 161–220 days after dose 2) and, if applicable, dose 3 (250+ days after dose 2 and after dose 3). No samples were collected 121–160 days after dose 2. If a patient had multiple antibody levels during a given time period, the last value was analyzed. Data are reported through December 1, 2021.

The present analysis includes data from 136 patients. Overall, 125 patients received a third mRNA-1273 dose, which was further classified as “full” (n=113) or booster (n=12); 11 patients did not receive a third dose. Third vaccinations were administered a median (interquartile range) of 247 (245–261) days and 235 (231–237) days after completion of the primary vaccination series for the full and booster doses, respectively.

Following the primary (2-dose) vaccination, median (interquartile range) antibody levels peaked within 15 days after the second dose (142 [37–381]). Thereafter, median antibody levels declined (Figure 1). At 161–220 days after dose 2, 54% of patients with available data had antibody indices >7. At this time point, rates of adequate antibody responses...
were 51% and 80% among those patients who would go on to receive full and booster doses, respectively, and 71% among those who would not receive a third dose.

Administration of a third dose of mRNA-1273 vaccine resulted in a marked increase in antibody levels, with median indices of 750 (maximum detectable index) a median of 26 days after administration. All but 3 patients administered a third dose (ie, 122/125; 98%) had antibody indices of >7 at follow-up. Among the 11 patients not receiving a third vaccine exposure, 3 (27%) had antibody indices ≤7.

More than 250 days after completion of the primary series, maximal antibody response was demonstrated in only 27% (3/11) of patients not receiving a third dose. In contrast, among patients administered a third dose (full or booster), 99.2% (124/125) demonstrated reactivity at follow-up and 51.2% (64/125) exhibited antibody levels at the maximum detectable level of 750. This antibody response exceeds that observed approximately 1 month after the second vaccine dose and is consistent with recent data on third doses of mRNA vaccines. Although the number of patients in the booster subgroup was small (n=12), the strong humoral response to a booster (50 mcg) dose appears comparable to that observed with a full third (100 mcg) dose: mean index (sd) was 564 (269) and 565 (237), for booster and additional dose, respectively.

Excluding patients who developed recognized COVID-19 infection during follow-up minimizes—but does not eliminate—the potential confounding effects of infection on antibody levels. Asymptomatic infection late in 2021 (coinciding with prevalence of the Omicron variant) may have contributed to the higher antibody indices observed late in the follow-up period. Other limitations include the absence of measures of clinical efficacy and cellular immunity. Importantly, there are no data to suggest that higher antibody index values indicate superior ability to neutralize the virus or fight infection.

Our results support the need for a third dose of mRNA-1273 vaccine, whether full or booster dose, for all eligible dialysis patients who received primary vaccination. Continued longitudinal research will help elucidate the need for, and optimal timing of, a fourth dose in this high-risk population.

### Ethical Approval

The purpose of this project was to a) implement a practice to improve the quality of patient care, and b) collect patient data regarding the implementation of clinical practice. Under the HHS regulations, these activities do not satisfy the definition of “research” under 45 CFR 46.102 (d). For this reason, no additional study-specific informed consent or institutional review board approval was required for this quality improvement project. This project was reviewed and determined to be quality improvement using standardized criteria from the Office of Human Research Protection. This process takes into account the project’s intent, design, funding, patient risk above standard of care, and protection of health information.
Acknowledgments
Medical writing and editing support was provided by Adam Perahia, MD, of NorthStar Strategic Consulting, LLC, via funding by Fresenius Medical Care.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This work was supported by Fresenius Medical Care.

Disclosure
LHF, JW, CM, MSA, and JLH are employees of Fresenius Medical Care, Global Medical Office. CJ is an employee of Spectra Laboratories. CM, MSA, and CJ, own stock in Fresenius Medical Care North America. MSA is the Chief Medical Officer of Fresenius Renal Therapies Group. JLH is the Global Head of Clinical Affairs for Fresenius Medical Care.

References